Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice

Molecular Therapy

Volumn 17, Issue 11, 2009, Pages 1979-1987

  Cho, Sun Wook ^a   Sun, Hyun Jin ^a   Yang, Jae Yeon ^a   Jung, Ju Yeon ^a   An, Jee Hyun ^a   Cho, Hwa Young ^a   Choi, Hyung Jin ^a   Kim, Sang Wan ^a   Kim, Seong Yeon ^a   Kim, Dohee ^b   Shin, Chan Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Dankook University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GREEN FLUORESCENT PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATE BUFFERED SALINE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM;

EPINEPHELUS MORIO; MUS;

EID: 70449123822     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.153     Document Type: Article

References (50)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001). Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785-795.
2. Miller, PD (2008). Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 22: 849-868.
3. Rossouw, JE, Anderson, GL, Prentice, RL, LaCroix, AZ, Kooperberg, C, Stefanick, ML et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 321-333.
4. Odvina, CV, Zerwekh, JE, Rao, DS, Maalouf, N, Gottschalk, FA and Pak CY (2005). Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301.
5. Gelse, K, von der Mark, K, Aigner, T, Park, J and Schneider, H (2003). Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells. Arthritis Rheum 48: 430-441.
6. Park, J, Ries, J, Gelse, K, Kloss, F, von der Mark, K, Wiltfang, J et al. (2003). Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: A comparison of adenoviral vectors and liposomes. Gene Ther 10: 1089-1098.
7. Van Damme, A, Chuah, MK, Dell'accio, F, De Bari, C, Luyten, F, Callen, D et al. (2003). Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats. Haemophilia 9: 94-103.
8. Tang, J, Xie, Q, Pan, G, Wang, J and Wang, M (2006). Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiathorac Surg 30: 353-361.
9. Porada, CD, Zanjani, ED and Almeida-Porad, G (2006). Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther 1: 365-369.
10. Perry, D (2000). Patients' voices: The powerful sound in the stem cell debate. Science 287: 1423.
11. Wada, T, Nakashima, T, Hiroshi, N and Penninger, JM (2006). RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25.
12. Bucay, N, Sarosi, I, Dunstan, CR, Morony, S, Tarpley, J, Capparelli, C et al. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268.
13. Burgess, TL, Qian, Y, Kaufman, S, Ring, BD, Van, G, Capparelli, C et al. (1999). The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527-538.
14. Dougall, WC, Glaccum, M, Charrier, K, Rohrbach, K, Brasel, K, De Smedt, T et al. (1999). RANK is ssential for osteoclast and lymph node development. Genes Dev 13: 2412-2424.
15. Li, J, Sarosi, I, Yan, XQ, Morony, S, Capparelli, C, Tan, HL et al (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastagenesis and regulation bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 1566-1571.
16. Kong, YY, Yoshida, H, Sarosi, I, Tan, HL, Timms, E, Capparelli, C et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
17. Hamdy, NA (2007). Targeting the RANK/RANKL/OPG signaling pathway: A novel approach in the management of osteoporosis. Curr Opin Investig Drugs 8: 299-303.
18. Zhang, J, Dai, J, Yao, Z, Lu, Y, Dougall, W and Keller, ET (2003). Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 7883-7890.
19. Hsu, H, Lacey, DL, Dunstan, CR, Solovyev, I, Colombero, A, Timms, E et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545.
20. Pearse, RN, Sordillo, EM, Yaccoby, S, Wong, BR, Liau, DF, Colman, N et al. (2001). Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98: 11581-11586.
21. Kim, D, Cho, SW, Her, SJ, Yang, JY, Kim, SW, Kim, SY et al. (2006). Retrovirus-mediated gene transfer of receptor activator of nuclear factor-κB-Fc prevents bone loss in ovariectomized mice. Stem Cells 24: 1798-1805.
22. Lapidot, T and Kollet, O (2002). The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immunedeficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16: 1992-2003.
23. Ponomaryov, T, Peled, A, Petit, I, Taichman, RS, Habler, L, Sandbank, J et al. (2000). Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106: 1331-1339.
24. Nagasawa, T, Kikutani, H and Kishimoto, T (1994). Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 91: 2305-2309.
25. Imai, K, Kobayashi, M, Wang, J, Ohim, Y, Hamada, J, Cho, Y et al. (1999). Selective transendothelial migration of hematopoietic progenitor cells: A role in homing of progenitor cells. Blood 93: 149-156.
26. Bleul, CC, Schultze, JL and Springer, TA (1998). B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med 187: 753-762.
27. Aiuti, A, Webb, IJ, Bleul, C, Spring, T and Gutierrez-Ramos, JC (1997). The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provided a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185: 111-120.
28. Pelletier, AJ, van der Laan, LJ, Hildbrand, P, Siani, MA, Thompson, DA, Dawson, PE et al. (2000). Presentation of chemokine SDF-1 α by fibronectin mediates directed migration of T cells. Blood 96 2682-2690.
29. Kucia, M, Reca, R, Miekus, K, Wanzeck, J, Wolakowski, W, Janowska-Wieczorek, A et al. (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanims: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23: 879-894.
30. Peled, A, Petit, I, Kollet, O, Magid, M, Ponomaryov, T, Byk, T et al (1999). Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283: 845-848.
31. Hall, JM and Korach, KS (2003). Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17 792-803.
32. Cranney, A, Tugwell, P, Adachi, J, Weaver, B, Zytaruk, N, Papaioannou, A et al. (2002). Meta-analyses of therapies for postmenopausal osteoporosis. III. Metaanalysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 517-523.
33. Cranney, A, Wells, G, Willan, A, Griffith, L, Zytanik, N, Robinson, V et al. (2002). Meta-analyses therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23: 508-516.
34. Ferguson, VL, Ayers, RA, Bateman, TA and Simske, SJ (2003). Bone development and age-related bone loss in male C57BL/6J mice. Bone 33: 387-398.
35. Beamer, WG, Donahue, LR, Rosen, CJ and Baylink, DJ (1996). Genetic variability in adult bone density among inbred strains of mice. Bone 18: 397-403.
36. Porecha, NK, English, K, Hangoc, G, Broxmeyer, HE and Christopherson, KW (2006). Enhanced function response to CXCL12/SDF-1 through retroviral overexpression of CXCR4 on M07e cells: Implications for hematopoietic stem cell transplantation. Stem Cells Dev 15: 325-333.
37. Kahn, J, Byk, T, Jansson-Sjostrand, L, Petit, I, Shivtiel, S, Nagler, A et al. (2004). Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103: 2942-2949.
38. Kollet, O, Shivtiel, S, Chen, YQ, Suriawinata, J, Thung, SN, Dabeva, MD et al. (2003). HGF, SDF-1, an MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest 112: 160-169.
39. Shi, M, Li, J, Liao, L, Chen, B, Li, B, Chen, L et al. (2007). Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Hoematolagica 92: 897-904.
40. Cheng, Z, Ou, L, Zhou, Z, Li, F, Jia, X, Zhang, Y et al. (2008). Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16 571-579.
41. Pasha, Z, Wan, Y, Sheikh, R, Zhang, D, Zhao, T and Ashraf, M (2008). Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 77: 134-442.
42. Gleichmann, Gillen, C, Czardybon, M, Bosse, F, Greiner-Petter, R, Auer, J et al. (2000). Cloning and characterization of SDF-1γ, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system. Eur J Neurosci 12: 1857-1866.
43. Taguchi, K, Ogawa, R, Migita, M, Hanawa, H, Ito, H and Orimo, H (2005). The role of bone marrow-derived cells in bone fracture repair in a green fluorescent protein chimeric mouse model. Biochem Biophys Res Commun 331: 31-36.
44. Devine, MJ, Mierisch, CM, Jang, E, Anderson, PC and Ballan, G (2002). Transplanted bone marrow cells localize to fracture callus in a mouse model. J Orthop Res 20: 1232-1239.
45. Hahn, JY, Cho, HJ, Kang, HJ, Kim, TS, Kim, MH, Chung, JH et al. (2008). Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cordial 51: 933-943.
46. Grauss, RW, Winter, EM, van Tuyn, J, Pijnappels, DA, Steijn, RV, Hogers, B et al. (2007). Mesenchymal stem cells from ischemic heart disease patients improve left ventricular function after acute myocardial infarction. Am J Physiol Heart Clin: Physiol 293: H2438-H2447.
47. Wang, Z, Goh, J, Das De, S, Ge, Z, Ouyang, H, Chong, JS et al. (2006). Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 12: 1753-1761.
48. Neal, JW and Clipstone, NA (2002). Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. J Biol Chem 277: 49776-49781.
49. Bellino, FL (2000). Nonprimate animal models of menopause: Workshop report. Menopause 7: 14-24.
50. Price, J (1987). Retroviruses and the study of cell lineage. Development 101: 409-419.